EGFR and lung cancer: Since the clinical efficacy of TKIs is ultimately limited by the development of acquired resistance, further investigation of novel molecular mechanisms is essential to develop strategies to overcome or delay the acquired resistance to TKIs in EGFR-mutant lung cancer.